Voyager Therapeutics (VYGR) Change in Receivables (2019 - 2026)
Voyager Therapeutics (VYGR) posted Change in Receivables of -$267000.0 for Q1 2026, up 81.26% sequentially from -$1.4 million in Q4 2025, and down 324.37% YoY from $119000.0 in Q1 2025.
Voyager Therapeutics (VYGR) Change in Receivables (2019 - 2026) Analysis & Trends
Voyager Therapeutics has reported Change in Receivables for 5 years, with the latest figure at -$267000.0 in Q1 2026.
- Quarterly Change in Receivables fell 324.37% year-over-year to -$267000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129000.0 (down 116.41% YoY) and the FY2025 annual result came in at $257000.0, up 100.33% from the prior year.
- Change in Receivables advanced to -$267000.0 in Q1 2026 per VYGR's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Change in Receivables peaked at $25.0 million in Q1 2023 and troughed at -$79.3 million in Q1 2024.
- A 4-year average of -$5.4 million and a median of $85000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables plunged 417.25% in 2024, then surged 100.15% in 2025.
- Over 4 years, Change in Receivables stood at $25.0 million in 2023, then plunged by 157.8% to -$14.4 million in 2024, then soared by 90.14% to -$1.4 million in 2025, then soared by 81.26% to -$267000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$267000.0, -$1.4 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Mn |
| Jun 30, 2026 | 1.44 Mn |
| Mar 31, 2026 | -267,000.00 |
| Mar 31, 2026 | -267,000.00 |
| Dec 31, 2025 | -1.43 Mn |
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | 51,000.00 |
| Jun 30, 2025 | 51,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | -14.45 Mn |
| Dec 31, 2024 | -14.45 Mn |
| Sep 30, 2024 | 14.25 Mn |
| Sep 30, 2024 | 14.25 Mn |
| Jun 30, 2024 | 865,000.00 |
| Jun 30, 2024 | 865,000.00 |
| Mar 31, 2024 | -79.31 Mn |
| Mar 31, 2024 | -79.31 Mn |